Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces Ensifentrine Meets Primary and Key Secondary Endpoints in Phase 3 ENHANCE-1 Trial for COPD
December 20, 2022 02:00 ET | Verona Pharma plc
Statistically significant improvements in lung function, symptoms and quality of life 36% reduction in rate of exacerbations over 24 weeks Well tolerated safety profile over 48 weeks NDA submission...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-1 Trial of Nebulized Ensifentrine for COPD
December 19, 2022 16:01 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Dec. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Reports Third Quarter 2022 Financial Results and Provides Corporate Update
November 09, 2022 02:00 ET | Verona Pharma plc
Access to up to $400 million expected to provide cash runway through at least 2025 Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 Conference call today at 9:00 a.m. EST / 2:00 p.m....
Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces November 2022 Investor Conference Participation
November 02, 2022 03:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will participate in the following...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Report Third Quarter 2022 Financial Results and Provide Corporate Update
October 26, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 26, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Secures Debt Financing of up to $150 Million from Oxford Finance
October 17, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 17, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces it has entered into a debt financing facility (“debt...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces Analyses Demonstrating Ensifentrine Reduced Exacerbation Rates Across Subgroups in Phase 3 ENHANCE-2 Trial for COPD
October 14, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Oct. 14, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces additional exacerbation* subgroup analyses from the Phase 3...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 29, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
Verona_Pharma_Dark_medium.jpg
Verona Pharma strengthens commercialization leadership team
August 24, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China
August 19, 2022 02:46 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...